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ABSTRACT 
Neuropsychiatric involvement in systemic lupus erythematosus (NPSLE) is a complex condition that 
remains poorly understood, and includes heterogeneous manifestations involving both the central and 
peripheral nervous system, with disabling effects. There are several models to improve NPSLE diagnosis 
when a neurological syndrome is present. In the last couple of years, the growing knowledge of the role of 
cytokines and antibodies in NPSLE, as well as the development of new functional imaging techniques, has 
brought some insights into the physiopathology of the disease, but their validation for clinical use remains 
undetermined. Furthermore, besides the classic clinical approach, a new tool for screening the 19 NPSLE 
syndromes has also been developed. Regarding NPSLE therapeutics, there is still no evidence-based 
treatment approach, but some data support the safety of biological medication when classic treatment fails. 
Despite the tendency to reclassify SLE patients in clinical and immunological subsets, we hope that these 
data will inspire medical professionals to approach NPSLE in a manner more tailored to the individual 
patient. 
KEY WORDS: Attribution models, functional magnetic resonance imaging, neuropsychiatric systemic 
lupus erythematosus 
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INTRODUCTION 
Neuropsychiatric involvement in systemic lupus 
erythematosus (SLE) was first described by Moriz 
Kaposi in 1872 in a young woman with disturbed 
neurological function, among other systemic mani-
festations. In 1903, Sir William Osler raised the 
hypothesis that cerebral vascular changes could be 
responsible for neurological involvement in SLE. 
Neuropsychiatric SLE (NPSLE) is currently 
described as “the most clinical challenging ‘visceral’ 
involvement,” “responsible for high morbidity and 
mortality,” and consequently posing a “great eco-
nomic and social burden.”1 
The condition has a broad spectrum of clinical 
manifestations and severity. The prevalence of 
NPSLE depends on which syndrome is present, and 
it is sometimes different from the prevalence of the 
same syndrome in the general population. In 1999 
the American College of Rheumatology (ACR) pro-
posed the most used and accepted nomenclature for 
NPSLE syndromes2 based on the previous classifi-
cation attempts of Kassan et al.3 and Singer et al.4 
They defined 19 different syndromes, distinguishing 
diffuse psychiatric/neuropsychological, and central 
and peripheral nervous system involvement,2 that 
could occur simultaneously or overlap in the same 
patient (Table 1, column one). 
As SLE is a chronic disease, the global approach 
to patient management should take into account the 
following: disease activity, the accrued damage, and 
the functional disability as measured by health-
related quality of life (HRQoL, the highest possible, 
Figure 1A). Each syndrome may present a different 
evolutionary pattern, increasing the complexity of 
clinical outcomes (Figure 1B).  
In 1991, rheumatologists interested in SLE 
formed the Systemic Lupus International Collabor-
ating Clinics (SLICC) group.5 The SLICC inception 
cohort has been collecting clinical data concerning 
several aspects of SLE, such as NPSLE, athero-
sclerosis, and damage, among others. 
The latest European League Against Rheumatism 
(EULAR) recommendations for the management of 
SLE with neuropsychiatric manifestations were 
published in 2010 and to date remain unrevised.6 
The clinical questions raised at the time were 
answered based on the literature published prior to 
January 2009.  
In recent years, many different physiopatho-
logical pathways have been described in SLE, as well 
as the role of different antibodies and functional 
imaging techniques. What remains unknown is how 
these developments contribute to a better under-
standing of NPSLE and how they may change the 
way we approach our patients. 
This paper provides a review of the main pub-
lished papers on NPSLE since the EULAR recom-
mendations were made, with the purpose of identi-
fying relevant data that may potentially change 
current clinical practice. 
PREVALENCE 
The prevalence of each NPSLE syndrome is highly 
variable across cohorts (Table 1),7–16 depending on 
patient selection method (population-based studies 
tend to gather less severe cases compared to tertiary 
center cohorts), on the nomenclature used to classi-
fy the event as NPSLE, and on whether or not the 
event is attributed to SLE, reaching a prevalence of 
almost 90%12 when every neuropsychiatric mani-
festation is attributed to NPSLE. Data from the first 
572 patients in the SLICC cohort17 showed that 28% 
of individuals experienced a NPSLE event in the first 
21 months of diagnosis; however, after analyzing the 
attribution of each event to SLE (see attribution 
models below), they concluded that only 6.1% was 
due to SLE itself. 
ARE NPSLE EVENTS DUE TO SLE ITSELF? 
ATTRIBUTION MODELS 
When a SLE patient presents with a neuropsychi-
atric event, there are several concurrent causes; dif-
ferent attribution models have been proposed to dis-
tinguish those events, depending on whether or not 
they are due to SLE. In the first population-based 
NPSLE prevalence study, Hanna Ainiala pointed out 
that if the minor and most common neuropsychi-
atric events (headache, mild depression, anxiety, 
minor cognitive complaints, and electromyography-
negative polyneuropathy) were excluded, then the 
prevalence of NPSLE would fall from 91% to 46%.7 
These minor events became known as the “Ainiala 
criteria” used as exclusion events in the most 
relevant attribution models.15,17 
The SLICC initiative NPSLE cohort led by 
Hanly17 defined factors that would indicate that the 
neuropsychiatric event was less likely to be related 
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to SLE: the temporal window of development (more 
than 6 months before the onset of SLE); the 
presence of concurrent non-SLE confounders that 
were most likely the cause or a significant 
contributor to the event (as defined by the ACR 
nomenclature); and the “Ainiala criteria.” The use of 
the narrower “model B” for attribution was 
responsible for the drop in the early NPSLE 
prevalence rate from 28% (when the broader “model 
A” was used) to 6.1%, and the drop in the cumulative 
NPSLE prevalence in the 1,047 patients of the SLICC 
cohort from 87.6% (model A) to 24.7% (model B).12 
Bortoluzziet al.,15 on behalf of The Italian Society 
of Rheumatology, developed a new algorithm (Table 
2) that added three advantages to Hanly’s attribu-
tion models: favoring factors that supported the 
attribution to SLE (derived from the rationale pres-
ented in the 2010 EULAR recommendations on 
SLE); a list of variables of confounders and favoring 
factors for each of the 19 ACR NPSLE syndromes; 
and a scoring system that provided a positive pre-
dictive value of 86.3%, a negative predictive value of 
85.7%, and a misclassification error of <10.0%. The 
diagnostic performance of this attribution algorithm 
was tested in the University of Heraklion SLE co-
hort, and it was superior to the other two models 
(i.e. Ainiala’s criteria and SLICC’s models A and B) 
in the major neuropsychiatric manifestations.18 
Like all other clinical situations, there is a need 
to understand the underlying cause of the neuro-
psychiatric event in each SLE patient in order to 
treat and prevent known complications and damage. 
 
Figure 1. Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) Manifestations Heterogeneity. 
A: The domains that should be taken into account when approaching specific or global manifestations in a patient. 
B: Examples of heterogeneity of a NPSLE manifestation regarding its dysfunction or burden over time.  
ACS, acute confusional syndrome; CVD, cerebrovascular disease; HRQoL, Health-related Quality of Life. 
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The main question is: when attributing to SLE, what 
are we attributing to? The knowledge of SLE patho-
physiology and the peculiarity of the broad mecha-
nisms of NPSLE should be pursued to ensure the 
most accurate tailored approach to each patient. 
PHYSIOPATHOLOGY 
To date, no single clear immunological pathway has 
been uncovered explaining why some SLE patients 
develop NPSLE and others do not. The main risk 
factors for NPSLE are general SLE activity or 
damage, previous NPSLE events, or other concur-
rent NPSLE syndromes.6 Although some mechan-
isms are common to focal and diffuse syndromes, 
there is a clear relationship between the presence of 
vasculopathy and antiphospholipid antibodies (aPL) 
and focal NPSLE (cerebrovascular disease, seizure, 
chorea, myelopathy), and between inflammatory 
mediators and diffuse NPSLE, but the mechanisms 
behind diffuse NPSLE are more elusive (Figure 2).19 
In clear contrast to other systemic manifestations of 
SLE, the presence of vasculitis is not a prominent 
feature of NPSLE.20 Instead, a bland vasculopathy 
with rare inflammatory infiltrates is characteristic of 
this syndrome, with growing evidence showing that 
blood–brain barrier (BBB) dysfunction may be 
essential to the development of NPSLE, allowing the 
passive diffusion of auto-reactive antibodies and 
cytokines, facilitating the development of a pro-
inflammatory milieu.21 
Blood–brain Barrier Dysfunction 
The BBB is an essential metabolically and immuno-
logically active barrier that controls the transport of 
molecules inside the central nervous system (CNS) 
and maintains an anti-inflammatory state. There is 
growing evidence supporting the presence of BBB 
dysfunction in NPSLE, considering the high levels of 
cytokines, albumin, and immunoglobulins in the 
cerebral spinal fluid (CSF) of these patients. Multi-
ple insults can cause transient BBB dysfunction, 
such as trauma, high blood pressure, and infection.21 
It has also been demonstrated that self-reactive 
autoantibodies can induce BBB dysfunction in 
vitro:20,22–24 anti-endothelial cell antibodies,22,24 
aPL, and anti-N-methyl-D-aspartate receptor 
through endothelial cell binding can induce BBB 
disruption, allowing passive diffusion of other auto-
antibodies into the CSF.20,23 This interaction might 
induce the production of pro-inflammatory chemo-
kines such as matrix metalloproteinase-8 (MMP-8) 
and plasminogen activator inhibitor-1, or cause 
endothelial cell dysfunction through the induction of 
the complement cascade.25 
Table 2. Bortoluzzi’s Attribution Algorithm, Categorization, and Weighting of Items Incorporated into the 
Algorithm. 
Item Score 
Item 1. Time of the onset of NP event with respect to SLE clinical onset 
 Before (>6 months before SLE onset) 
 Concomitant (within 6 months of SLE onset) 
 After (>6 months of SLE event) 
 
0 
3 
2 
Item 2. Minor or not specific NP events as defined by Ainiala 
 Present  
 Absent 
 
0 
3 
Item 3. Confounding factors or not SLE-related associations as defined by the ACR glossary 
 None or not applicable 
 Present (one confounding factor) 
 Present (more than one confounding factor) 
 
2 
1 
0 
Item 4. Additional (or favoring factors) 
 None or not applicable 
 Present (one additional or favoring factor) 
 Present (more than one additional or favoring factor) 
 
0 
1 
2 
ACR, American College of Rheumatology; NP, neuropsychiatric; SLE, systemic lupus erythematosus. 
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Several complement components have been 
associated with NPSLE: complement C3 with diffuse 
manifestations and complement C4 with focal 
NPSLE, although only with the concomitant pres-
ence of aPL.26 Specifically, complement C5a may 
contribute to BBB dysfunction by inducing the pro-
duction of pro-inflammatory cytokines, promoting 
reactive oxygen species formation, and prompting 
actin reorganization.20 
Another marker of BBB dysfunction is the 
development of a pro-inflammatory status detri-
mental to the brain tissue. The cytokine tumor 
necrosis factor-like weak inducer of apoptosis 
through its receptor fibroblast growth factor-
inducible 14 has been associated with the develop-
ment of BBB dysfunction in NPSLE.21,27  Soluble α 
klotho protein has been shown to have low levels in 
CSF, not only in NPSLE patients but also in other 
CNS inflammatory diseases (multiple sclerosis and 
neuromyelitis optica), suggesting a common role in 
neuroinflammatory modulation.28 
Interferon α (IFNα) levels have been shown to be 
elevated in CSF (but not in serum) in NPSLE 
patients compared with SLE patients without neuro-
psychiatric manifestations. This elevation was corre-
lated with the presence of interferon gamma-
induced protein 10, interleukin 8 (IL-8), and mono-
cyte chemoattractant protein-1 (MCP-1) in the CSF, 
cytokines/chemokines induced by IFNα and capable 
of inducing BBB dysfunction.29,30 Interferon gamma-
induced protein 10 receptor (CXCR3) is expressed 
mainly in type 1 T helper cells that might suggest a 
preferential stimulation of this pathway; however, 
no studies have clarified which T helper response 
 
Figure 2. Pathophysiology of Neuropsychiatric (NP) Systemic Lupus Erythematosus (NPSLE). 
Focal and diffuse NPSLE differ in their pathophysiology. In the former, there is a great association with thrombotic 
events frequently in the context of antiphospholipid (aPL) antibodies positivity with very occasional contribution of 
leukostasis and vasculitis. In the latter, a more complex picture arises: systemic production of antibodies that can 
induce neuronal damage either directly or through induction of blood–brain barrier (BBB) dysfunction which allows 
passive diffusion of antibodies to the cerebrospinal fluid (CSF); activation cascade; and the development of a 
complex in situ pro-inflammatory milieu including activation of interferon α cascade. Final neurotoxicity may be 
mediated by induction of apoptosis, antibody-mediated damage, or excitotoxicity by receptor-agonistic binding 
(anti-NMDA).  
Abs, antibodies; anti-P rib, anti-P ribosomal antibodies; anti-Sm, anti-Smith antibodies; aEC, anti-endothelial cells 
antibodies; BBB, blood–brain barrier; CSF, cerebrospinal fluid. 
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predominates in NPSLE.31 One study has also 
demonstrated that the antibody-antigen interaction 
inside the brain triggers a positive feedback loop 
that stimulates the production of pro-inflammatory 
cytokines like IFNα.32 
Autoantibodies 
A growing number of self-reactive antibodies (in 
serum and CSF) have been associated with NPSLE, 
possibly with pathogenic roles.25,33 
Antiphospholipid antibodies have been linked to 
NPSLE, especially through the induction of throm-
bosis causing focal manifestations of NPSLE.19 How-
ever, this pro-thrombotic effect cannot explain the 
relation of aPL with diffuse NPSLE.34 It has been 
shown that through their interaction with endothe-
lial cells they can induce BBB dysfunction, having a 
synergic effect with other antibodies; additionally, 
they may bind neuronal cells and induce neurotox-
icity.22 
Anti-dsDNA antibodies, a specific marker of SLE 
activity, have been detected in CSF of NPSLE 
patients and proven to bind hippocampal neurons.35 
A subset of anti-dsDNA antibodies have been shown 
to interact with a subunit of anti-N-methyl-D-
aspartate and its receptor; these complexes have 
been related to mood disorders, acute confusional 
state (when in high titers), and cognitive decline 
including memory dysfunction.20,36 These antibodies 
may induce neuronal death by complement cascade 
activation and induce cellular calcium overload and 
neurotoxicity similar to that occurring in Alzhei-
mer’s disease. In mice it has been demonstrated that 
this action can be blocked by an anti-N-methyl-D-
aspartate receptor antagonist (memantine).37 How-
ever, in a study of SLE patients with cognitive 
dysfunction, those in treatment with memantine did 
not have better cognitive outcomes.25 
The cross-reactivity of dsDNA with anti-N-
methyl-D-aspartate receptor is an example of how 
antigenic mimicry may contribute to the patho-
genesis of autoimmune diseases. Another example is 
the cross-reactive binding of the anti-ribosomal P 
protein with neuronal surface antigens (neuronal 
growth-associated protein 43).22 These antibodies 
have been shown to interact with endothelial cells, 
and, in particular, they specifically target the hippo-
campus and the amygdala, which possibly explains 
its association with depression and cognitive dys-
function. However, there has been contradictory 
evidence linking anti-ribosomal P protein to NPSLE 
manifestations.22,29 Anti-Smith antigen antibodies 
(anti-Sm) have been shown to cross-react with anti-
ribosomal P protein and are specifically associated 
with acute confusional state.36 
Anti-ribonucleoprotein (RNP1) titers in CSF 
have been associated with the presence of neuro-
psychiatric manifestations in both SLE and mixed 
connective tissue disease.38 Anti-aquaporin 4 is a 
marker of neuromyelitis optica (Devic’s disease), a 
multiple sclerosis-like disease that can occur on its 
own or be a manifestation of NPSLE.23 Anti-
glyceraldehyde 3-phosphate dehydrogenase was 
found to be a marker of schizophrenia and depres-
sion both in patients with and without SLE and to 
directly induce dendritic atrophy and cognitive and 
emotional dysfunction in mice after intrathecal 
injection.39 
Anti-SSA and anti-P ribosomal antibodies were 
found in CSF of NPSLE patients and correlated with 
NPSLE manifestations, compared to SLE patients 
with no neuropsychiatric manifestations.40 Anti-
microtubule-associated protein-2, anti-glial fibril-
lary acid protein, anti-C1q, anti-lymphocytotoxic 
antibodies, and anti-ganglioside antibodies have 
been inconsistently associated with various NPSLE 
syndromes.22,25,29,41 
Systemic versus Local Production of 
Antibodies  
The apparent role of antibodies in NPSLE raises the 
question as to whether they are produced system-
ically and passively diffused to the CSF through a 
dysfunctional BBB, or if they are locally produced 
inside the CNS. The association of high CSF 
antibodies titers (anti-Sm and anti-ribosomal P pro-
tein) with increased levels of CSF albumin, together 
with the evidence of BBB dysfunction, supports the 
hypothesis of passive diffusion.36 On the other hand, 
a study with anti-N-methyl-D-aspartate receptor has 
supported the role of locally produced antibodies as 
suggested by the increased ratio of CSF/serum anti-
bodies.42 Other studies have demonstrated an 
association between high CSF levels of B cell surviv-
ing factors (a proliferation-inducing ligand (APRIL) 
and B cell-activating factor (BAFF)) and NPSLE 
manifestations that may support local production of 
antibodies by B cells.43 
Genes and NPSLE Risk 
Genetic studies are very difficult in heterogeneous 
diseases such as SLE. Nevertheless, some insights 
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have come to light in the past couple of years. The 
discovery of the TREX1 gene (IFN regulator gene), 
responsible for Aicardi–Goutières syndrome, led to 
the recognition of association between several 
polymorphisms in heterozygotes with high NPSLE 
risk.44  The TRPC6 gene, involved in the regulation 
of  N-methyl-D-aspartate receptor, seems to be 
protective of NPSLE manifestations.45 
NPSLE: SCREENING, DIAGNOSIS AND 
MONITORING 
In clinical practice, NPSLE is usually diagnosed 
when the patient is symptomatic (based on patient 
complaints or the physician’s assessment). In clin-
ical trials and inception cohorts, several screening 
protocols have been used, including general queries, 
mood disorders, and cognitive dysfunction scales, 
which are time-consuming and difficult to use in 
routine clinical practice. Mosca et al. developed a 
simple self-assessment screening tool for NPSLE in 
routine clinical practice with 27 questions for the 19 
ACR NPSLE syndromes that capture sub-clinical 
involvement.46 A score above 17 was considered as 
suggestive of the presence of NPSLE with a sensi-
tivity of 92.9% (95% CI 85.1%–97.3%) and speci-
ficity of 25.4% (95% CI 14.7%–39.00%). Efforts have 
been made to validate it in different countries. 
The initial diagnosis workup for NPSLE mani-
festation is the same as for the same syndrome in 
non-SLE patients and depends upon the type of 
neuropsychiatric manifestation. The complementary 
exams are done mainly for exclusion of other diag-
noses, as none of the results are specific of NPSLE.6 
The neuropsychological assessment of cognitive 
function should be done not only for diagnosis but 
also to have a neuropsychiatric baseline for monitor-
ing the patient’s status over time.  
When EULAR recommendations for NPSLE 
management6 were compared with the usual care in 
a tertiary rheumatology center, an overutilization of 
magnetic resonance imaging (MRI) and suboptimal 
evaluation of cognitive dysfunction were noted in 
clinical practice as compared to the recommenda-
tions.47 
IMAGING TECHNIQUES IN NPSLE 
Magnetic resonance imaging (MRI) has become the 
gold standard tool for NPSLE assessment, replacing 
computed tomography (CT) in the evaluation of brain 
pathology among these patients. Despite its low 
specificity for neuroradiological findings in NPSLE, 
MRI has proved to have a sufficient level of accuracy 
and has the advantage of allowing the exclusion of 
other neurological conditions. The average sensitivity 
of MRI in active NPSLE is 57%, and the recom-
mended MRI protocol (brain and spinal cord) 
includes conventional MRI sequences—T1/T2, fluid-
attenuated inversion recovery, diffusion-weighted 
imaging, and gadolinium-enhanced T1 sequence.6 A 
wide variety of conventional MRI findings have been 
previously described, albeit more than half of patients 
with NPSLE present a normal MRI.48 
The MRI changes described in NPSLE patients 
range from small punctate focal lesions in white 
matter, defined as white matter hyperintensities, to 
severe large lesions. Abnormal findings may be di-
vided in three groups, according to their pathophysi-
ology and imaging features: small-vessel disease, 
large-vessel disease, and inflammatory-like lesions.49 
Small vessel disease, which accounts for 30%–
75% of MRI findings in NPSLE, includes white mat-
ter hyperintensities, cortical brain atrophy, lacunes, 
small subcortical infarcts, and microbleeds,50,51 with 
white matter hyperintensities being the most com-
monly documented in SLE patients. The majority of 
small vessel lesions are often considered non-specific, 
as they may be related to age, hypertension, disease 
duration, low complement, aPL antibodies, and the 
presence of NPSLE manifestations, mainly cognitive 
dysfunction, seizures, and cerebrovascular disease.52 
Given their non-specificity, part of the white matter 
hyperintensities observed in patients with active 
NPSLE do not seem to be related to SLE and are not 
responsible for neurological symptoms, while a sig-
nificant percent of these lesions are transitory and 
disappear with time and immunosuppressive thera-
py.48 In patients with a more severe disease, white 
matter hyperintensities may be a consequence of 
central nervous system damage and progress over 
time.51 Signs of cortical atrophy in the MRI usually 
occur concurrently with other small vessel lesions.52 
Cortical atrophy seems to correlate with disease 
duration, cognitive dysfunction, cerebrovascular 
disease, seizure,53 low complement, and lupus anti-
coagulant; some studies also found a significant 
positive association with corticosteroid therapy.48,52 
Large vessel disease is considerably less frequent 
than small vessel lesions and accounts for 10%–15% 
of NPSLE MRI findings.48 Large vessel disease 
causes medium to large size vessel infarcts, which 
can be single or multiple, extending through a vas-
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cular territory, and involving both the grey and 
white matter.51 
Inflammatory-like lesions are rather less common, 
accounting to for 5%–10% of NPSLE.54 Myelitis is a 
rare manifestation of NPSLE  that affects 1%–5% of 
SLE patients, despite being a serious complication of 
the disease with a variable outcome. Contrast-
enhanced spinal cord MRI also helps to exclude cord 
compression, and brain MRI is recommended when 
other NPSLE symptoms or signs coexist, as well as in 
the differential diagnosis of demyelinating disorders. 
Moreover, when there is a suspected cranial neurop-
athy, MRI is crucial for evaluation of optic nerve 
enhancement and brain abnormalities. 
Functional Imaging as a Tool to Pursue 
NPSLE Mechanisms 
Despite the utility of conventional MRI for evalua-
tion of neurologic symptoms of SLE patients, the 
lack of sensitivity of this neuroimaging method has 
led to the exploration of other techniques. More 
advanced methods of neuroimaging might be per-
formed when conventional MRI does not contribute 
to explain neurologic signs and symptoms in SLE 
patients and are also useful to distinguish between 
acute and chronic lesions. These neuroimaging tech-
niques include quantitative MRI, such as magnetic 
resonance spectroscopy, magnetization transfer 
imaging, diffusion tensor imaging, and diffusion-
weighted imaging, or fluorodeoxyglucose positron 
emission tomography (FDG-PET) and single photon 
emission CT (SPECT). 
Magnetic resonance spectroscopy is a recent 
modality that can non-invasively quantify some 
brain biochemical compounds such as reduction in 
N-acetyl aspartate representing neuronal or axonal 
dysfunction or loss.55 Reduction in N-acetyl aspar-
tate seems to correlate with cerebral atrophy and 
neurocognitive dysfunction, especially in SLE 
patients with aPL antibodies,55,56 but no strong 
correlation with global disease activity has been 
described so far. 
Diffusion tensor imaging and diffusion-weighted 
imaging are non-invasive MRI techniques that mea-
sure the diffusion of water in the brain, assessing the 
white matter structure and integrity. Diffusion-
weighted imaging has shown abnormal diffusivity 
consistent with inflammation and loss of white mat-
ter integrity; it also allowed discernment between 
inflammatory and ischemic lesions in SLE patients. 
Nevertheless, this technique does not contribute 
significantly to the distinction from other causes of 
ischemic or inflammatory lesions.57 Magnetization 
transfer imaging quantifies the exchange of protons 
between those bound in macromolecules, like 
cholesterol in myelin, and free water. However, the 
application of these techniques to NPSLE is still 
quite limited.  
Several studies have demonstrated FDG-PET 
hypometabolism in at least one brain region of 
patients with major or minor CNS symptoms, main-
ly in parietal, temporal, fronto-temporal, and central 
regions.58 These findings are particularly important 
for patients with depressive symptoms related to 
NPSLE, since in these cases brain hypometabolism 
is preferentially detected in the parieto-occipital re-
gion, while in patients with primary depression the 
location of hypometabolic lesions is commonly 
found in bilateral insula and basal ganglia.57 Some 
authors have also described an improvement of 
clinical and FDG-PET findings with immuno-
suppressive therapy among these patients.58,59 
The SPECT modality provides an estimate of 
regional cerebral blood flow, metabolism, and 
neuronal activity and is extremely sensitive in the 
detection of abnormalities. Among NPSLE patients 
SPECT has identified diffuse and focal deficits, but 
they are not specific and do not always correlate 
with neuropsychiatric manifestations. The most 
notable SPECT abnormality in patients with major 
NPSLE is patchy diffuse hypoperfusion, mainly 
associated with acute major NPSLE events, whereas 
focal lesions appear to be more common in patients 
with longer duration of disease. Both FDG-PET and 
SPECT have been explored as functional imaging 
tools in lupus and appear to be sensitive in detecting 
subtle brain changes in NPSLE. Nonetheless, both 
techniques, especially SPECT, have low specificity, 
which limits their use in clinical practice.55 
Considering the multifactorial basis of brain 
disease in SLE patients, its diagnosis remains a chal-
lenge. Therefore, a multimodal approach, including 
a combination of both morphological and functional 
imaging, may improve the current knowledge of 
metabolic and structural changes related to NPSLE 
syndromes. 
MANAGEMENT 
The management of NPSLE must be directed at the 
type of neuropsychiatric event (among the 19 
NPSLE syndromes) and its characteristics: acute 
versus chronic; predominantly vascular versus 
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inflammatory; minor versus severe; active and 
ongoing versus damage (Figure 3). 
Very few studies have been conducted assessing 
the role of drugs in the prevention of NPSLE events. 
In the LUMINA cohort,60 hydroxychloroquine and 
moderate prednisolone dose delayed the first 
NPSLE manifestation, regardless of the type of 
event. The SALUD study61  showed that aspirin im-
proved cognitive function in older patients with risk 
factors. In our cohort,62 the odds of having cognitive 
impairment was significantly lower for patients 
taking hydroxychloroquine (adjusted odds ratio 
0.368; P=0.036) even when controlling for other 
covariates (i.e. education, disease duration, and 
neuropsychiatric involvement), and among patients 
without NPSLE (n=96) the odds of having cognitive 
impairment remained significantly lower for pa-
tients taking hydroxychloroquine when controlled 
for other covariates (i.e. education, disease duration, 
anxiety, and depression).  
When the neuropsychiatric event is acute and 
diffuse, it is presumably mainly inflammatory and 
almost always associated with generalized SLE ac-
tivity. In this scenario, SLE global activity should be 
controlled at the same time as NPSLE is assessed,6 
and if NPSLE is severe (acute confusional state, 
seizures, encephalitis) it should be treated with 
immunosuppressive drugs. There are no strong data 
supporting one or another immunosuppressor. 
Steroids have been used in several different doses, 
from prednisolone 0.5–1 mg/kg/day to bolus of 
endovenous methylprednisolone 3–5 days of 500 
mg to 1 g/day.63,64 There are several case series, 
open label studies, and one observational trial 
supporting the use of cyclophosphamide,65 and the 
most described regimens are the low-dose 
EuroLupus regimen endovenous 500 mg every other 
week for six cycles and the USA National Institutes 
of Health regimen of 1 g/monthly for 6 months. A 
Cochrane Review showed that there is very little 
evidence that cyclophosphamide has better 
 
Figure 3. Treatment Approach to Neuropsychiatric (NP) Systemic Lupus Erythematosus (NPSLE). 
Diffuse or focal NP presentations may arise (1) directly as a result of autoimmune mechanisms (primary NPSLE), in 
which case treatment should target the most relevant pathologic mechanism (anticoagulation in aPL-associated 
thrombosis or immunosuppression in antibody-mediated diffuse damage); (2) secondary to complications of the 
disease or treatment (secondary NPSLE), which may require treatment such as antibiotic therapy for bacterial 
infection; and (3) finally as a consequence of NP events related to SLE, which may have specific treatment.  
HCQ, hydroxychloroquine. 
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outcomes than methylprednisolone alone.66 There 
are case series reporting the use of azathioprine in 
maintenance treatment after cyclophosphamide or 
high-dose steroids in severe NPSLE,64 and a few 
case reports of patients that were successfully 
treated with mycophenolate mofetil.64,67 A recent 
revision summarized the positive effects of 
rituximab (with high rates of response) and 
belimumab in severe NPSLE.68 In severe refractory 
cases, intravenous immunoglobulin69,70 and 
plasmapheresis71,72 have been successfully used as 
bridge therapy, mainly when infection is not 
completely ruled out, in pregnant patients, or when 
there are life-threatening symptoms.  
If the patient has a focal neuropsychiatric 
syndrome, there is a high probability of aPL posi-
tivity. In these cases, ischemic and cerebral venous 
thrombotic events should be anticoagulated.73 Other 
focal syndromes (seizures, chorea, and transverse 
myelopathy) are also patterns of microvascular 
disease, and they might benefit from antiplatelet 
drugs or anticoagulation. If there are other clinical 
or laboratorial signs of inflammation, additional 
immunosuppression should be considered. The 
most suitable management for these patients should 
be decided case by case. Despite these recommenda-
tions, not every NPSLE manifestation requires im-
munosuppressive treatment. When Pamfil et al. 
audited the usual care in NPSLE against EULAR 
recommendations in two tertiary centers,47  they 
found that 52% of cerebrovascular events were over-
treated with immunosuppressive therapy in addition 
to antithrombotic treatment.47 
Symptomatic adjuvant therapy is generally need-
ed to control either severe (acute confusional syn-
dromes, psychosis, seizures, chorea) or minor neu-
ropsychiatric syndromes (anxiety, mood disorders, 
headache) (Figure 3).6 These patients should be 
managed by a multidisciplinary team led by a rheu-
matologist/internal medicine expert and including a 
neurologist, psychiatrist, psychologist, and physio-
therapist.  
CONCLUSIONS 
With the growing knowledge and recognition of 
different heterogenic syndromes under the shared 
title of NPSLE there is an unmet need for reclassifi-
cation of NPSLE patients according to both clinical 
phenotypes and immunological profile. As such, the 
NPSLE attribution might change from the disease 
(SLE or not) to the related pathophysiology: anti-
aquaporin-4 attribution, anti-N-methyl-D-aspartate 
receptor attribution, aPL attribution, anti-P ribo-
some attribution, anti-SSA attribution, etc. The 
holistic approach to each patient with NPSLE should 
be commenced, taking into account patients’ SLE-
related conditions and comorbidities, the probable 
role of SLE physiopathology, and the need for 
specific treatment. 
In the future, and as more data become available, 
we will hopefully be able to tailor the approach and 
management of NPSLE based on the clinical 
presentation, immunological phenotype, and 
genotype pattern. 
REFERENCES 
1. Adelman DC, Saltiel E, Klinenberg JR. The neuro-
psychiatric manifestations of systemic lupus erythe-
matosus: an overview. Semin Arthritis Rheum 1986; 
15:185–99. Full Text 
2. The American College of Rheumatology nomen-
clature and case definitions for neuropsychiatric 
lupus syndromes. Arthritis Rheum 1999;42:599–608. 
Full Text 
3. Kassan SS, Lockshin MD. Central nervous system 
lupus erythematosus. The need for classification. 
Arthritis Rheum 1979;22:1382–5. Full Text 
4. Singer J, Denburg JA. Diagnostic criteria for neuro-
psychiatric systemic lupus erythematosus: the results 
of a consensus meeting. The Ad Hoc Neuropsychi-
atric Lupus Workshop Group. J Rheumatol 1990; 
17:1397–402. 
5. Isenberg DA, Gladman D. The Systemic Lupus 
International Collaborating Clinics Group--origins 
and outcomes. Lupus 2001;10:375–7. Full Text 
6. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR 
recommendations for the management of systemic 
lupus erythematosus with neuropsychiatric mani-
festations: report of a task force of the EULAR stand-
ing committee for clinical affairs. Ann Rheum Dis 
2010;69:2074–82. Full Text 
7. Ainiala H, Loukkola J, Peltola J, Korpela M, Hieta-
harju A. The prevalence of neuropsychiatric syn-
dromes in systemic lupus erythematosus. Neurology 
2001;57:496–500. Full Text 
8. Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neu-
ropsychiatric manifestations in systemic lupus 
erythematosus: prevalence and association with anti-
phospholipid antibodies. J Rheumatol 2003;30:985–
92. 
9. Brey RL, Holliday SL, Saklad AR, et al. Neuropsychi-
atric syndromes in lupus: prevalence using standard-
 NPSLE: A Tailored Approach? 
 
 
Rambam Maimonides Medical Journal 12 January 2017  Volume 8  Issue 1  e0001 
 
ized definitions. Neurology 2002;58:1214–20. Full 
Text 
10. Afeltra A, Garzia P, Mitterhofer AP, et al. Neuro-
psychiatric lupus syndromes: relationship with anti-
phospholipid antibodies. Neurology 2003;61:108–10. 
Full Text 
11. Costallat LT, Bertelo M, Dritsa M. The American 
College of Rheumatology (ACR) nomenclature and 
case definitions for neuropsychiatric lupus syndrome. 
Analysis of 527 patients. Lupus 2001;10(S32):10. 
12. Hanly JG, Urowitz MB, Su L, et al. Prospective 
analysis of neuropsychiatric events in an internation-
al disease inception cohort of patients with systemic 
lupus erythematosus. Ann Rheum Dis 2010;69:529–
35. Full Text 
13. Mok CC, To CH, Mak A. Neuropsychiatric damage in 
Southern Chinese patients with systemic lupus 
erythematosus. Medicine (Baltimore) 2006;85:221–
8. Full Text 
14. Steup-Beekman GM, Zirkzee EJ, Cohen D, et al. 
Neuropsychiatric manifestations in patients with 
systemic lupus erythematosus: epidemiology and 
radiology pointing to an immune-mediated cause. 
Ann Rheum Dis 2013;72(Suppl 2):ii76–9. Full Text 
15. Bortoluzzi A, Scire CA, Bombardieri S, et al. Develop-
ment and validation of a new algorithm for attribu-
tion of neuropsychiatric events in systemic lupus 
erythematosus. Rheumatology (Oxford) 2015;54:891-
8. Full Text 
16. Faria RF, Samões R, Marinho A, et al. Neuropsychi-
atric (NP) manifestations in systemic lupus erythe-
matosus (SLE) and antiphospholipid syndrome (APS) 
– clinical experience of a single center. Lupus 
2013;22(S1):140. 
17. Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. 
Neuropsychiatric events at the time of diagnosis of 
systemic lupus erythematosus: an international 
inception cohort study. Arthritis Rheum 2007;56: 
265–73. Full Text 
18. Fanouriakis A, Pamfil C, Rednic S, Sidiropoulos P, 
Bertsias G, Boumpas DT. Is it primary neuropsychi-
atric systemic lupus erythematosus? Performance of 
existing attribution models using physician judgment 
as the gold standard. Clin Exp Rheumatol 2016;34: 
910–17. 
19. Hanly JG. Diagnosis and management of neuro-
psychiatric SLE. Nat Rev Rheumatol 2014;10:338–
47. Full Text 
20. Govoni M, Bortoluzzi A, Padovan M, et al. The diag-
nosis and clinical management of the neuropsychi-
atric manifestations of lupus. J Autoimmun 2016;74: 
41–72. Full Text 
21. Stock AD, Wen J, Putterman C. Neuropsychiatric 
lupus, the blood brain barrier, and the TWEAK/Fn14 
pathway. Front Immunol 2013;4:484. Full Text 
22. Perricone C, Pendolino M, Olivieri M, Conti F, 
Valesini G, Alessandri C. Neuropsychiatric manifesta-
tions associated with anti-endothelial cell antibodies 
in systemic lupus erythematosus. Isr Med Assoc J 
2015;17:171–8. 
23. Costallat BL, Ferreira DM, Costallat LT, Appenzeller 
S. Myelopathy in systemic lupus erythematosus: 
clinical, laboratory, radiological and progression 
findings in a cohort of 1,193 patients. Rev Bras 
Reumatol Engl Ed 2016;56:240–51. Full Text 
24. Wang JB, Li H, Wang LL, Liang HD, Zhao L, Dong J. 
Role of IL-1β, IL-6, IL-8 and IFN-γ in pathogenesis of 
central nervous system neuropsychiatric systemic 
lupus erythematous. Int J Clin Exp Med 2015;8: 
16658–63. 
25. Ho RC, Thiaghu C, Ong H, et al. A meta-analysis of 
serum and cerebrospinal fluid autoantibodies in 
neuropsychiatric systemic lupus erythematosus. 
Autoimmun Rev 2016;15:124–38. Full Text 
26. Magro-Checa C, Schaarenburg RA, Beaart HJ, 
Huizinga TW, Steup-Beekman GM, Trouw LA. 
Complement levels and anti-C1q autoantibodies in 
patients with neuropsychiatric systemic lupus 
erythematosus. Lupus 2016;25:878–88. Full Text 
27. Fragoso-Loyo H, Atisha-Fregoso Y, Nunez-Alvarez 
CA, Llorente L. Utility of TWEAK to assess 
neuropsychiatric disease activity in systemic lupus 
erhytematosus. Lupus 2016;25:364–9. Full Text 
28. Ushigusa T, Ichinose K, Sato S, et al. Soluble α-klotho 
is a potential biomarker associated with neuropsychi-
atric systemic lupus erythematosus. Clin Immunol 
2016;165:29–34. Full Text 
29. Kivity S, Agmon-Levin N, Zandman-Goddard G, 
Chapman J, Shoenfeld Y. Neuropsychiatric lupus: a 
mosaic of clinical presentations. BMC Med 2015;13: 
43. Full Text 
30. Yoshio T, Okamoto H, Kurasawa K, Dei Y, Hirohata 
S, Minota S. IL-6, IL-8, IP-10, MCP-1 and G-CSF are 
significantly increased in cerebrospinal fluid but not 
in sera of patients with central neuropsychiatric lupus 
erythematosus. Lupus 2016;25:997–1003. Full Text 
31. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P. 
Structure-function relationship between the human 
chemokine receptor CXCR3 and its ligands. J Biol 
Chem 2003;278:289–95. Full Text 
32. Santer DM, Yoshio T, Minota S, Moller T, Elkon KB. 
Potent induction of IFN-alpha and chemokines by 
autoantibodies in the cerebrospinal fluid of patients 
with neuropsychiatric lupus. J Immunol 2009;182: 
1192–201. Full Text 
 NPSLE: A Tailored Approach? 
 
 
Rambam Maimonides Medical Journal 13 January 2017  Volume 8  Issue 1  e0001 
 
33. Xu J, Cheng Y, Lai A, et al. Autoantibodies affect 
brain density reduction in non neuropsychiatric 
systemic lupus erythematosus patients. J Immunol 
Res 2015;2015:920718. Full Text 
34. Noureldine MH, Harifi G, Berjawi A, et al. Hughes 
syndrome and epilepsy: when to test for antiphos-
pholipid antibodies? Lupus 2016 May 25. pii: 
0961203316651747. [Epub ahead of print].  
35. Gerosa M, Poletti B, Pregnolato F, et al. Antigluta-
mate receptor antibodies and cognitive impairment 
in primary antiphospholipid syndrome and systemic 
lupus erythematosus. Front Immunol 2016;7:5. Full 
Text 
36. Hirohata S, Sakuma Y, Yanagida T, Yoshio T. Associ-
ation of cerebrospinal fluid anti-Sm antibodies with 
acute confusional state in systemic lupus erythe-
matosus. Arthritis Res Ther 2014;16:450. Full Text 
37. Popescu A, Kao AH. Neuropsychiatric systemic lupus 
erythematosus. Current Neuropharmacol 2011;9: 
449–57. Full Text 
38. Sato T, Fujii T, Yokoyama T, et al. Anti-U1 RNP 
antibodies in cerebrospinal fluid are associated with 
central neuropsychiatric manifestations in systemic 
lupus erythematosus and mixed connective tissue 
disease. Arthritis Rheum 2010;62:3730–40. Full Text 
39. Delunardo F, Soldati D, Bellisario V, et al. Anti-
GAPDH autoantibodies as a pathogenic determinant 
and potential biomarker of neuropsychiatric diseases. 
Arthritis Rheumatol 2016;68:2708–16. Full Text 
40. Hu C, Huang W, Chen H, et al. Autoantibody pro-
filing on human proteome microarray for biomarker 
discovery in cerebrospinal fluid and sera of neuro-
psychiatric lupus. PLoS One 2015;10:e0126643. Full 
Text 
41. Yamada Y, Nozawa K, Nakano S, et al. Antibodies to 
microtubule-associated protein-2 in the cerebro-
spinal fluid are a useful diagnostic biomarker for 
neuropsychiatric systemic lupus erythematosus. Mod 
Rheumatol 2016;26:562–8. Full Text 
42. Gulati G, Iffland PH 2nd, Janigro D, Zhang B, Luggen 
ME. Anti-NR2 antibodies, blood-brain barrier, and 
cognitive dysfunction. Clin Rheumatol 2016;35: 
2989–97. Full Text 
43. George-Chandy A, Trysberg E, Eriksson K. Raised 
intrathecal levels of APRIL and BAFF in patients with 
systemic lupus erythematosus: relationship to neuro-
psychiatric symptoms. Arthritis Res Ther 2008;10: 
R97. Full Text 
44. Fredi M, Bianchi M, Andreoli L, et al. Typing TREX1 
gene in patients with systemic lupus erythematosus. 
Reumatismo 2015;67:1–7. Full Text 
45. Ramirez GA, Lanzani C, Bozzolo EP, et al. TRPC6 
gene variants and neuropsychiatric lupus. J 
Neuroimmunol 2015;288:21–4. Full Text 
46. Mosca M, Govoni M, Tomietto P, et al. The develop-
ment of a simple questionnaire to screen patients 
with SLE for the presence of neuropsychiatric symp-
toms in routine clinical practice. Lupus 2011;20:485–
92. Full Text 
47. Pamfil C, Fanouriakis A, Damian L, et al. EULAR rec-
ommendations for neuropsychiatric systemic lupus 
erythematosus vs usual care: results from two Euro-
pean centres. Rheumatology (Oxford) 2015;54:1270–
8. Full Text 
48. Sarbu N, Alobeidi F, Toledano P, et al. Brain abnor-
malities in newly diagnosed neuropsychiatric lupus: 
systematic MRI approach and correlation with clin-
ical and laboratory data in a large multicenter cohort. 
Autoimmun Rev 2015;14:153–9. Full Text 
49. Sarbu N, Bargalló N, Cervera R. Advanced and 
conventional magnetic resonance imaging in 
neuropsychiatric lupus. Version 2. F1000Res. 2015 
Jun 23 [revised 2015 Jul 28];4:162. 
50. Luyendijk J, Steens SC, Ouwendijk WJ, et al. 
Neuropsychiatric systemic lupus erythematosus: 
lessons learned from magnetic resonance imaging. 
Arthritis Rheum 2011;63:722–32. Full Text 
51. Appenzeller S, Vasconcelos Faria A, Li LM, Costallat 
LT, Cendes F. Quantitative magnetic resonance 
imaging analyses and clinical significance of 
hyperintense white matter lesions in systemic lupus 
erythematosus patients. Ann Neurol 2008;64:635–
43. Full Text 
52. Appenzeller S, Pike GB, Clarke AE. Magnetic reso-
nance imaging in the evaluation of central nervous 
system manifestations in systemic lupus erythema-
tosus. Clin Rev Allergy Immunol 2008;34:361–6. Full 
Text 
53. Ainiala H, Dastidar P, Loukkola J, et al. Cerebral MRI 
abnormalities and their association with neuro-
psychiatric manifestations in SLE: a population-
based study. Scand J Rheumatol 2005;34:376–82. 
Full Text 
54. Bertsias GK, Boumpas DT. Pathogenesis, diagnosis 
and management of neuropsychiatric SLE manifesta-
tions. Nat Rev Rheumatol 2010;6:358–67. Full Text 
55. Peterson PL, Axford JS, Isenberg D. Imaging in CNS 
lupus. Best Pract Res Clin Rheumatol 2005;19:727–
39. Full Text 
56. Sabet A, Sibbitt WL, Stidley CA, Danska J, Brooks 
WM. Neurometabolite markers of cerebral injury in 
the antiphospholipid antibody syndrome of systemic 
 NPSLE: A Tailored Approach? 
 
 
Rambam Maimonides Medical Journal 14 January 2017  Volume 8  Issue 1  e0001 
 
lupus erythematosus. Stroke 1998;29:2254–60. Full 
Text 
57. Gal Y, Twig G, Mozes O, Greenberg G, Hoffmann C, 
Shoenfeld Y. Central nervous system involvement in 
systemic lupus erythematosus: an imaging challenge. 
Isr Med Assoc J 2013;15:382–6. 
58. Weiner S, Otte A, Schumacher M, et al. Diagnosis and 
monitoring of central nervous system involvement in 
systemic lupus erythematosus: value of F-18 
fluorodeoxyglucose PET. Ann Rheum Dis 
2000;59:377–85. Full Text 
59. Saito T, Hama M, Chiba Y, et al. Brain FDG-PET 
reflecting clinical course of depression induced by 
systemic lupus erythematosus: two case reports. J 
Neurol Sci 2015;358:464–6. Full Text 
60. Gonzalez LA, Pons-Estel GJ, Zhang J, et al. Time to 
neuropsychiatric damage occurrence in LUMINA 
(LXVI): a multi-ethnic lupus cohort. Lupus 2009;18: 
822–30. Full Text 
61. McLaurin EY, Holliday SL, Williams P, Brey RL. 
Predictors of cognitive dysfunction in patients with 
systemic lupus erythematosus. Neurology 2005;64: 
297–303. Full Text 
62. Cavaco S, Martins da Silva A, Santos E, et al. 
Hydroxychloroquine and cognition in systemic lupus 
erythematosus. Lupus 2014;23. 
63. Kamen DL, Zollars ES. Corticosteroids in lupus 
nephritis and central nervous system lupus. Rheum 
Dis Clin North Am 2016;42:63–73,viii. Full Text 
64. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-
Beekman GM. Management of neuropsychiatric 
systemic lupus erythematosus: current approaches 
and future perspectives. Drugs 2016;76:459–83. Full 
Text 
65. Fanouriakis A, Pamfil C, Sidiropoulos P, et al. Cyclo-
phosphamide in combination with glucocorticoids for 
severe neuropsychiatric systemic lupus erythema-
tosus: a retrospective, observational two-centre 
study. Lupus 2016;25:627–36. Full Text 
66. Fernandes Moca Trevisani V, Castro AA, Ferreira 
Neves Neto J, Atallah AAN. Cyclophosphamide 
versus methylprednisolone for treating neuropsychi-
atric involvement in systemic lupus erythematosus. 
Cochrane Database Syst Rev 2013;(2):CD002265. 
Full Text 
67. Higashioka K, Yoshida K, Oryoji K, et al. Successful 
treatment of lupus cerebrovascular disease with 
mycophenolate mofetil. Intern Med 2015;54:2255–9. 
Full Text 
68. Farinha F, Abrol E, Isenberg DA. Biologic therapies 
in patients with neuropsychiatric systemic lupus 
erythematosus. Lupus 2016;25:1278–9. Full Text 
69. Toubi E, Castle A, Shoenfeld Y. High dose intra-
venous immunoglobulins: an option in the treatment 
of systemic lupus erythematosus. Hum Immunol 
2005;66:395–402. Full Text 
70. Milstone AM, Meyers K, Elia J. Treatment of acute 
neuropsychiatric lupus with intravenous immunolo-
globulin (IVIG): a case report and review of the 
literature. Clin Rheumatol 2005;24:394–7. Full Text 
71. Neuwelt CM. The role of plasmapheresis in the treat-
ment of severe central nervous system neuropsychi-
atric systemic lupus erythematosus. Ther Apher Dial 
2003;7:173–82. Full Text 
72. Bartolucci P, Brechignac S, Cohen P, Le Guern V, 
Guillevin L. Adjunctive plasma exchanges to treat 
neuropsychiatric lupus: a retrospective study on 10 
patients. Lupus 2007;16:817–22. Full Text 
73. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A syste-
matic review of secondary thromboprophylaxis in 
patients with antiphospholipid antibodies. Arthritis 
Rheum 2007;57:1487–95. Full Text 
